FDA sends complete response letter to MannKind regarding new inhaler
January 21st 2011FDA has sent MannKind Corp. a complete response letter regarding the company?s New Drug Application for Afrezza (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with types 1 and 2 diabetes for the control of hyperglycemia.
Merck halts vorapaxar study over bleeding concerns in stroke victims
January 21st 2011Concern that its drug vorapaxar, in trial for its potential to prevent clots, actually increased the risk of bleeding in stroke victims has prompted Merck & Co. to halt a late-stage study of the drug, the Associated Press reported.
FDA OKs label update for etravirine
January 20th 2011FDA has approved a label update to include a 200-mg formulation of etravirine (Intelence, Tibotec Therapeutics), a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 in adults resistant to an NNRTI and other antiretroviral agents.
Generic competition on the horizon as many pharmaceutical companies face patent expirations
January 20th 2011The impact of generic drugs ? which now account for more than 70% of all prescriptions dispensed in the United States ? will continue to increase as some of the world?s most-prescribed products lose their patent protection in 2011 and begin facing generic competition.
FDA approves head lice treatment for children and adults
January 19th 2011FDA approved spinosad (Natroba, ParaPRO LLC) Topical Suspension 0.9% for the treatment of head lice infestation in patients aged 4 years and older. Natroba is a topical drug product and should be applied only to the child's scalp or hair.
FDA: Severe liver injury associated with dronedarone use
January 18th 2011Severe liver injury, including 2 cases of acute liver failure leading to liver transplant in patients treated with the medication, has been associated with the use of dronedarone (Multaq), according to an FDA Drug Safety Communication announcement.
NCPA applauds BB&T Corporation for preserving employees' choice in filling maintenance prescriptions
January 18th 2011The National Community Pharmacists Association commended BB&T Corporation's recent decision to reemphasize and continue its employees' choice in filling their maintenance prescriptions, including at independent community pharmacies.
HIV oral pre-exposure prophylaxis trial shows promise
January 18th 2011The first trial to provide evidence that drugs used to treat HIV can also help to prevent HIV infection among men who have sex with men (when combined with other prevention strategies) was reported late November online in the New England Journal of Medicine.
Longer oral contraceptive regimens containing a progestogen show higher effectiveness
January 18th 2011Compared with conventional 21-day regimens, 24-day oral contraceptive regimens containing a progestogen with a long half-life show higher contraceptive effectiveness under routine medical conditions, according to research published in the January 2011 issue of Obstetrics & Gynecology.
Oncology buy-and-bill evolving
January 15th 2011Oncology treatment and benefits are changing. Buy-and-bill, the traditional methodology that had physicians buying chemotherapeutic products, treating in the office, and billing the payer, is going the way of surgery by barbers. But no one is quite sure what will replace the one-time standard of payment.
Medical marijuana and patient counseling
January 15th 2011Under the federal Controlled Substances Act, marijuana is classified as Schedule I, a definition that gives it a high potential for abuse, with no current safe or medical use. Meanwhile, in 14 states, patients have access to medical marijuana upon physican recommendation.
FDA approves ready-to-use 750-mg dosage of vancomycin
January 14th 2011FDA has approved the premix formulation of vancomycin injection, USP (750 mg/150 mL) (Baxter). Vancomycin is an antibiotic used to treat severe infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus and/or treat patients who are penicillin-resistant.
New 3-drug regimen improves outcomes for myeloma patients
January 13th 2011The addition of bortezomib to the standard induction therapy before double autologous stem-cell transplantation for patients with multiple myeloma appears to improve nearly threefold the rates of complete or near-complete response, according to research published online in The Lancet, HealthDay News reported.
Increased reduction in LDL cholesterol lessens vascular events
January 11th 2011Further reductions in LDL cholesterol through more intensive statin regimens safely produce definite further reductions in vascular events, even down to very low LDL levels, lower than current targets, according to the results of 2 meta-analyses, The Lancet reported. There was no evidence of any lower threshold where the benefit is not seen.
Many new cancer drugs require updated safety labels
January 11th 2011Many serious or potentially fatal adverse reactions associated with new, targeted anti-cancer agents are not reported in the original published research on the drug, and they are not known to oncologists until years later when drug labels are updated, including boxed warnings, according to research published online in the Journal of Clinical Oncology, HealthDay News reported.
Combining statins and fibrates increases rhabdomyolysis risk
January 6th 2011Patients who are newly treated with statin-fibrate concurrent therapy are slightly more likely to be hospitalized with rhabdomyolysis than those who take just one of the medications, according to research published in the American Journal of Cardiology, HealthDay News reported.
Many new cancer drugs require updated safety labels
January 6th 2011Many serious or potentially fatal adverse reactions associated with new, targeted anti-cancer agents are not reported in the original published research on the drug, and they are not known to oncologists until years later when drug labels are updated, including boxed warnings, according to research published online in the Journal of Clinical Oncology, HealthDay News reported.